Recursion Pharmaceuticals Inc
RXRXHealthcare|Biotechnology|USA
$3.56
-0.21 (-5.57%)
Tangible Book
$1.08
About
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
Stock Price
-37.6%(1Y)
Pipeline Summary
9 total trials5
Phase 1
7
Phase 2
1
Phase 3
0
Phase 4
Recruiting: 5Completed: 1Terminated: 3
Active Trials (5)
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
NCT06678659Unresectable
Phase 1Phase 2Recruiting
Enrollment: 170 participants
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
NCT07517198Solid Tumor
Phase 1Recruiting
Enrollment: 40 participants
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
NCT06980116Relapsed or Refractory B-cell Malignancies
Phase 1Recruiting
Enrollment: 85 participants
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
NCT05985655Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 1Phase 2Recruiting
Enrollment: 230 participants
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
NCT05552755Familial Adenomatous Polyposis
Phase 1Phase 2Recruiting
Enrollment: 67 participants
BioScore
4.2/10
Cautious
Ownership
Recent Insider Trades
Borgeson BlakeSELL
2026-07-0740,000 shares @ $3.96
Bumpus NamandjeSELL
2026-06-183,963 shares @ $3.18
Khan NajatSELL
2026-06-0523,588 shares @ $3.58
Gibson ChristopherSELL
2026-06-0540,000 shares @ $3.62
Bumpus NamandjeSELL
2026-06-034,386 shares @ $3.54
Recent News
2026-07-10 00:02:46
2026-07-06 11:57:31
2026-07-01 14:58:32
2026-06-25 02:50:27
2026-06-18 00:00:11
Data last updated: Jul 13, 2026, 12:45 PM